Autolus Therapeutics plc Net Income
Autolus Therapeutics plc (AUTL) reported Net Income of -$39.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-11
- Autolus Therapeutics plc net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$39.11M.
- Autolus Therapeutics plc net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$71.60M.
- Autolus Therapeutics plc net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$90.33M.
- Autolus Therapeutics plc net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$79.12M.
- Autolus Therapeutics plc net income (loss) attributable to parent for fiscal 2025 was -$287.53M.
- Autolus Therapeutics plc net income (loss) attributable to parent for fiscal 2024 was -$220.66M.
- Autolus Therapeutics plc net income (loss) attributable to parent for fiscal 2023 was -$208.38M.
- Autolus Therapeutics plc net income (loss) attributable to parent for fiscal 2022 was -$148.84M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 15 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$39.11M 10-Q · filed 2026-08-11 | -$110.71M 10-Q · filed 2026-08-11 | -$201.04M derived: sum of 3 quarters · filed 2026-08-11 | -$280.16M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | -$71.60M 10-Q · filed 2026-08-11 | -$161.93M derived: sum of 2 quarters · filed 2026-08-11 | -$241.05M derived: sum of 3 quarters · filed 2026-08-11 | -$288.96M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-12-31 | -$90.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$169.45M derived: sum of 2 quarters · filed 2026-03-27 | -$217.37M derived: sum of 3 quarters · filed 2026-08-11 | -$287.53M 10-K · filed 2026-03-27 | ||
| 2025-09-30 | -$79.12M 10-Q · filed 2025-11-12 | -$127.03M derived: sum of 2 quarters · filed 2026-08-11 | -$197.20M 10-Q · filed 2025-11-12 | -$224.80M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | -$47.92M 10-Q · filed 2026-08-11 | -$118.08M 10-Q · filed 2026-08-11 | -$145.68M derived: sum of 3 quarters · filed 2026-08-11 | -$227.78M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | -$70.16M 10-Q · filed 2026-08-11 | -$97.77M derived: sum of 2 quarters · filed 2026-08-11 | -$179.86M derived: sum of 3 quarters · filed 2026-08-11 | -$238.13M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2024-12-31 | -$27.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$109.70M derived: sum of 2 quarters · filed 2026-03-27 | -$167.97M derived: sum of 3 quarters · filed 2026-03-27 | -$220.66M 10-K · filed 2026-03-27 | ||
| 2024-09-30 | -$82.09M 10-Q · filed 2025-11-12 | -$140.37M derived: sum of 2 quarters · filed 2025-11-12 | -$193.06M 10-Q · filed 2025-11-12 | -$270.23M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | -$58.27M 10-Q · filed 2025-08-12 | -$110.96M 10-Q · filed 2025-08-12 | -$188.13M derived: sum of 3 quarters · filed 2025-08-12 | -$233.98M derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | -$52.69M 10-Q · filed 2025-08-12 | -$129.86M derived: sum of 2 quarters · filed 2025-08-12 | -$175.71M derived: sum of 3 quarters · filed 2025-08-12 | -$221.26M derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2023-12-31 | -$77.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$123.02M derived: sum of 2 quarters · filed 2025-03-20 | -$168.57M derived: sum of 3 quarters · filed 2025-03-20 | -$208.38M 10-K · filed 2025-03-20 | ||
| 2023-09-30 | -$45.85M 10-Q · filed 2024-11-12 | -$91.40M derived: sum of 2 quarters · filed 2024-11-12 | -$131.21M 10-Q · filed 2024-11-12 | -$158.16M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | -$45.55M 10-Q · filed 2024-08-08 | -$85.36M 10-Q · filed 2024-08-08 | -$112.31M derived: sum of 3 quarters · filed 2024-08-08 | -$155.08M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | -$39.81M 10-Q · filed 2024-08-08 | -$66.76M derived: sum of 2 quarters · filed 2024-08-08 | -$109.53M derived: sum of 3 quarters · filed 2024-08-08 | -$151.59M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2022-12-31 | -$26.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$69.72M derived: sum of 2 quarters · filed 2024-03-21 | -$111.78M derived: sum of 3 quarters · filed 2024-03-21 | -$148.84M 10-K · filed 2024-03-21 | ||
| 2022-09-30 | -$42.77M 10-K · filed 2024-03-21 | -$84.83M derived: sum of 2 quarters · filed 2024-03-21 | -$121.89M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$42.06M 10-K · filed 2024-03-21 | -$79.12M derived: sum of 2 quarters · filed 2024-03-21 | ||||
| 2022-03-31 | -$37.06M 10-K · filed 2024-03-21 | |||||
| 2021-12-31 | -$142.10M 10-K · filed 2024-03-21 | |||||
| 2021-03-31 | -$33.27M 6-K · filed 2021-05-06 | -$76.13M derived: sum of 2 quarters · filed 2023-03-07 | -$113.44M derived: sum of 3 quarters · filed 2023-03-07 | -$145.49M derived: sum of 4 quarters · filed 2023-03-07 | ||
| 2020-12-31 | -$42.86M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-07 | -$80.18M derived: sum of 2 quarters · filed 2023-03-07 | -$112.22M derived: sum of 3 quarters · filed 2023-03-07 | -$142.09M 20-F · filed 2023-03-07 | ||
| 2020-09-30 | -$37.31M 6-K · filed 2020-11-05 | -$69.36M derived: sum of 2 quarters · filed 2020-11-05 | -$99.23M 6-K · filed 2020-11-05 | -$140.18M derived: sum of 4 quarters · filed 2022-03-10 | ||
| 2020-06-30 | -$32.05M 6-K · filed 2020-08-06 | -$61.92M 6-K · filed 2020-08-06 | -$102.86M derived: sum of 3 quarters · filed 2022-03-10 | -$130.11M derived: sum of 4 quarters · filed 2022-03-10 | ||
| 2020-03-31 | -$29.87M 6-K · filed 2021-05-06 | -$70.82M derived: sum of 2 quarters · filed 2022-03-10 | -$98.06M derived: sum of 3 quarters · filed 2022-03-10 | -$126.54M derived: sum of 4 quarters · filed 2022-03-10 | ||
| 2019-12-31 | -$40.94M derived: 20-F 12 month − 6-K 9 month · filed 2022-03-10 | -$68.19M derived: sum of 2 quarters · filed 2022-03-10 | -$96.67M derived: sum of 3 quarters · filed 2022-03-10 | -$123.85M 20-F · filed 2022-03-10 | ||
| 2019-09-30 | -$27.25M 6-K · filed 2020-11-05 | -$55.73M derived: sum of 2 quarters · filed 2020-11-05 | -$82.91M 6-K · filed 2020-11-05 | -$103.55M derived: sum of 4 quarters · filed 2021-03-04 | ||
| 2019-06-30 | -$28.48M 6-K · filed 2020-08-06 | -$55.66M 6-K · filed 2020-08-06 | -$76.31M derived: sum of 3 quarters · filed 2021-03-04 | -$89.17M derived: sum of 4 quarters · filed 2021-03-04 | ||
| 2019-03-31 | -$27.18M 6-K · filed 2020-08-06 | -$47.83M derived: sum of 2 quarters · filed 2021-03-04 | -$60.69M derived: sum of 3 quarters · filed 2021-03-04 | -$68.34M derived: sum of 4 quarters · filed 2021-03-04 | ||
| 2018-12-31 | -$20.65M 20-F · filed 2021-03-04 | -$33.51M derived: sum of 2 quarters · filed 2021-03-04 | -$41.16M derived: sum of 3 quarters · filed 2021-03-04 | -$57.88M derived: sum of 4 quarters · filed 2021-03-04 | ||
| 2018-09-30 | -$12.86M 6-K · filed 2019-11-07 | -$20.51M derived: sum of 2 quarters · filed 2019-11-07 | -$44.75M 20-F · filed 2021-03-04 | -$37.23M 6-K · filed 2019-11-07 | -$44.75M 20-F · filed 2021-03-04 | |
| 2018-06-30 | -$7.65M 6-K · filed 2019-08-08 | -$24.37M 6-K · filed 2019-08-08 | -$31.89M derived: sum of 3 quarters · filed 2019-08-08 | |||
| 2018-03-31 | -$16.72M 6-K · filed 2019-08-08 | -$24.24M derived: sum of 2 quarters · filed 2019-08-08 | ||||
| 2017-12-31 | -$7.52M 20-F · filed 2019-02-25 | -$19.73M 20-F · filed 2020-03-03 | ||||
| 2017-09-30 | -$19.73M 20-F · filed 2020-03-03 | |||||
| 2016-09-30 | -$12.55M 20-F · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |